Angiotensin-(1-7) dosage and evidence
Written by Aaron CuhaReviewed Sep 2026
The short answer
Angiotensin-(1-7) is the brake on the body's main blood pressure system.
Evidence grade for Angiotensin-(1-7): Limited. The rule: people have taken it in a published study, but fewer than 100 of them. The sum on this page: 5 completed trials, 76 people given it. A grade counts how much has been done to people, not whether it works.
- People given it
- 76
- Human studies
- 5
- Found nothing
- 1
Dose
No human dose established
Amounts that were given in studies sit in Human evidence on this page. None of them is a personal dose.
5 completed trials, 76 people given it
3 effects reported, 2 unwanted, 1 wanted, by people using it, not a trial
Goal pages: Ageing and longevity, Heart and circulation, Immune system and inflammation
In plain English
In plain English, from Aaron
This is how I would explain it to a friend. The evidence, with the numbers, is further down the page.
Angiotensin-(1-7) is a small hormone that acts as the brake on your main blood pressure system. It is made from angiotensin II. It is sold with claims about heart repair and longer life. It is not approved anywhere.
What people take it for
- Protecting the heart.
- Fighting scarring and repairing tissue.
- Living longer.
What studies in people showed
The human studies were in cancer, transplants and COVID-19, not in the things it is sold for. The largest was in COVID-19 intensive care, with 107 people across two stages. It did not work, and it stopped early because too few people joined. In 20 people with sarcoma that had spread, it did not change the course of the cancer. In the first study, 18 adults with advanced cancer got daily shots. At the top dose, one had a severe stroke and another had nerve damage that healed. Heart and scarring claims come from rats and mice.
What people report
Reports, not study results
The good
- In the first cancer study, one tumour shrank and three more held steady for over three months.
The bad
- At the top dose, one person had a severe stroke and another had nerve damage in the head.
- One person in the COVID-19 study had a slow heartbeat that may have come from the drug.
Where these come from: No user reports. These come from the cancer and COVID-19 studies on this page.
My bottom line
The only people given this were very sick, and the top dose caused a stroke. There is no human reason to inject it for heart health or ageing.
An opinion, not a finding. I am a coach, not a doctor.
What it has been measured to do
Measured in people
Goals Angiotensin-(1-7) has been tested for in people, biggest studies first. We count only what the studies on this page say, so the real numbers may be higher.
- Cancer and tumours38 people · 2 studies
- Living longer20 people · 1 study
- Heart attacks and strokes18 people · 1 study
33 of the 36 indexed goals have no study of any kind behind Angiotensin-(1-7)
No study in people, animals or cells on this page reports a result for these. That does not prove Angiotensin-(1-7) does nothing for them. It does mean anything you have heard about Angiotensin-(1-7) and one of these did not come from a study cited here.
Show full evidence
What is Angiotensin-(1-7)?
Angiotensin-(1-7) is the brake on the body's main blood pressure system. It is made from angiotensin II. It has been given to people in studies of cancer, transplants and COVID-19. In the first cancer study, the top dose caused a stroke in one person and nerve damage in another that later healed. Most of the company's studies were stopped or cancelled.
Angiotensin-(1-7) is a small hormone, 7 building blocks long. The enzyme ACE2 cuts it from angiotensin II. It works through a receptor called Mas. It pushes against the vessel-squeezing, scar-building side of the same system. That push-back is the whole basis for the claims about longer life and tissue repair. Those claims are not what has been tested in people.
What has been tested in people is cancer, blood count recovery after transplant, and COVID-19. The largest study was in intensive care during COVID-19. It signed up 28 people in a first stage and 79 in a second stage, then stopped early because too few people joined. In the second stage, days without extra oxygen did not clearly differ between groups (a typical 19 against 14 days). A study in 20 people with sarcoma that had spread found the cancer held off for 2.7 months on average. People lived 10.2 months on average. It did not repeat a blood marker effect seen in the first study. That first study gave daily shots under the skin to 18 adults with advanced cancer. At 700 micrograms per kilogram, one person had a severe stroke and another had nerve damage in the head that healed. The dose chosen for later studies was 400 micrograms per kilogram.
It is not approved anywhere, for anything. The company program, under the code TXA127, ran a string of small studies. Several were stopped because too few people joined. Three were cancelled before anyone signed up.
How does Angiotensin-(1-7) work?
In people, ACE2 turns angiotensin II into angiotensin-(1-7). It then docks on the Mas receptor. What we know about it in people is thin. The first cancer study measured its level in the blood. It also found a drop in a blood marker called placental growth factor in the patients who did better. The sarcoma study confirmed the level in the blood rose 4 hours after a shot. It did not repeat the marker drop. The claims that it fights scarring and protects the heart come from rat and mouse work. Do not read them as human findings.
What have studies in people found about Angiotensin-(1-7)?
People have been given this peptide in at least four published studies, plus a set of small registered studies. There was an early study in advanced cancer and a dose study around breast cancer chemo. There was a study in sarcoma that had spread, and a study in intensive care during COVID-19. None of it looks at the uses the peptide is sold for.
- COVID-19 intensive care study, 79 people in the main stage: no clear difference in days without extra oxygen (a typical 19 against 14 days). It stopped early because too few people joined. The good-looking figure quoted elsewhere comes from lumping the open first stage in with the main stage after the fact.
- Sarcoma study, 20 adults with cancer that had spread, 20 mg daily: people coped with it. The cancer held off for 2.7 months on average, and people lived 10.2 months on average. The blood marker signal from the first study did not repeat.
- First study, 18 adults with advanced cancer: a severe stroke and nerve damage in the head that healed, both at 700 micrograms per kilogram. Other side effects were mostly mild. The dose chosen for later studies was 400 micrograms per kilogram.
- A dose study around chemo in women newly diagnosed with breast cancer.
- Registry, checked 11 September 2026: of the TXA127 studies listed, three were cancelled with nobody signed up. Three were stopped early, one for trouble filling a dose group and one because too few people could join. The current Duchenne heart study is listed as status unknown. None of the finished studies has posted results in the registry.
What this does not tell you: Nothing here tests heart protection, scarring, tissue repair or ageing in people. Those are the claims made for this peptide outside the clinic. The studies that exist are small, in very sick people, and mostly had no comparison group. Several were stopped before they could answer anything. The one serious brain and nerve warning comes from a cancer dose study. So we do not know how it applies to other doses or other people. That is a reason to be careful, not a reason to relax.
The state of the research
The gap between this peptide's reputation and its record in people teaches a lot. The Mas receptor story is real biology. ACE2 makes angiotensin-(1-7), and it pushes back against the vessel-squeezing side of the system. In rats and mice it fights scarring and widens blood vessels. Two separate companies built programs on that, and the registry shows what happened. Tarix Pharmaceuticals ran transplant and blood count studies. Three were cancelled before a single person joined, and two were stopped because too few people joined. Constant Therapeutics later registered stroke and Duchenne heart studies, and their status has not been confirmed.
A 7 building block piece of a human hormone is also hard to own. That shapes who will pay for a study. The result is a pile of small studies in groups picked because someone would fund them, not because they were the best test of the idea. That explains why the record is thin. It does not show the peptide does nothing. It is also not evidence that it does anything. And the stroke and nerve damage in the first study are a reminder that a natural peptide given at drug doses is still a drug.
The evidence, in charts
Fig. 1a · how many people
76people, across 4 studies in people cited here
| Study | People | Share |
|---|---|---|
| Annals of Intensive Care 2024 | 28 | 37% |
| Sarcoma 2016 | 20 | 26% |
| Clinical Cancer Research 2009 | 18 | 24% |
| ClinicalTrials.gov 2023 | 10 | 13% |
Counts are the number of people each study on this page says it signed up. That includes studies that only watched people and gave nobody the compound. 3 more studies in people give no headcount and are not counted here. Studies still signing people up are left out, and only studies cited on this page are counted.
Fig. 1b · evidence mix
7 of 8 sources here are studies in people. The rest is not.
- Study in people · done in people788%
- Review of studies · sums up other studies113%
Counted from the list of sources on this page. It counts only what we cite, so there may be more studies out there. A review counts once, however many studies it sums up.
Fig. 2 · evidence over time
The studies cover 7 different years, 2006 to 2024, counted from the list of sources on this page.
Fig. 3 · legal status at a glance
US
Not approved
UK
Not approved
AU
Not approved
CA
Not approved
Not approved in any of the four countries shown. This is what the law says, not a verdict on the science. See Legal status below for the full text and any notes.
Fig. 4 · how much does what
Nobody has tested different amounts in people
This chart would show how the effect changes as the amount goes up. For this compound, nobody has measured that in people. So we leave it empty. We will not borrow an animal chart and pretend it works the same in people.
Fig. 5 · what the molecule is
- Kind of compound
- Peptide
- Molecule weight
- Not on file
- Half-life
- None on file
- Chain length
- None on file
No amino acid sequence is on file for Angiotensin-(1-7), so none is drawn rather than guessed from a name.
The studies we cite
- Study in people2009Phase I and pharmacokinetic study of angiotensin-(1-7), an endogenous antiangiogenic hormone
The first test in people was about safety, and it turned up serious harm at the top dose. 18 adults with advanced cancer got the peptide as a shot under the skin, daily for five days, with the dose raised group by group. At the highest dose one person had a severe stroke and another lost nerve function in the head, which recovered. One tumour shrank and three more stopped growing for over three months. These were very ill people and there was no comparison group.
18 adults with advanced solid tumours received escalating subcutaneous doses daily for 5 days on a 3 week cycle. Dose-limiting toxicities at 700 micrograms per kilogram were a grade 4 stroke and a grade 3 reversible cranial neuropathy. One patient had a 19 percent tumour reduction and 3 more had disease stabilisation beyond 3 months. Recommended phase 2 dose 400 micrograms per kilogram.
- Study in people2016Phase II Trial of Angiotensin-(1-7) for the Treatment of Patients with Metastatic Sarcoma
Given alone to people with an advanced cancer, it did not change the course of the disease. 20 people with sarcoma that had spread got a daily shot under the skin. Their cancer held off for about 2.7 months on average and they lived about 10.2 months. Two people with blood vessel tumours stayed stable far longer. A blood marker effect seen in the first study did not show up again. Everybody got the drug, so there is nothing to compare these figures against.
20 people with metastatic sarcoma received 20 mg subcutaneously daily. Median progression-free survival 2.7 months (95 percent confidence interval 1.4 to 4.1) and median overall survival 10.2 months (5.3 to 18.3). The placental growth factor biomarker effect seen in phase 1 was not confirmed. Two people with vascular sarcomas had prolonged disease stabilisation at 10 and 19 months.
- Study in people2024Angiotensin-(1-7) infusion in COVID-19 patients admitted to the ICU: a seamless phase 1-2 randomized clinical trial
It was tested in intensive care during COVID-19 and it did not work. 28 people took part in an open first stage. 79 took part in a second stage where nobody involved knew who got the drug. The study stopped early because too few people joined. Days free of extra oxygen came out about the same in the second stage. A figure favouring the drug exists, but only from lumping the two stages together after the fact. One person had a slow heartbeat, possibly caused by the drug.
Investigator-initiated trial in two intensive care units: 28 people in the open-label phase 1 and 79 in the double-blind randomised phase 2, stopped early for slow recruitment. Oxygen-free days by day 28 did not differ in phase 2 (median 19 versus 14 days, p = 0.15). Pooling both phases gave a difference favouring treatment (p = 0.04), which is a post-hoc pooled comparison rather than the randomised result. One serious adverse event, bradycardia, was judged possibly related.
- Study in people2006Phase I/II dose escalation study of angiotensin 1-7 administered before and after chemotherapy in patients with newly diagnosed breast cancer
This tested whether the peptide could protect blood counts through chemotherapy, and at one dose it did. 15 women newly diagnosed with breast cancer got one of five doses around their chemotherapy. Five more got filgrastim, the standard drug for this job, as a comparison. Nobody had to stop for side effects. At 100 micrograms per kilogram, fewer patients had low platelets, low red cells or low white cells than on the standard drug. Three patients per dose is far too few to settle anything.
Randomised multicentre dose-escalation study giving angiotensin-(1-7) around chemotherapy in newly diagnosed breast cancer, one of the earliest human exposures to this peptide.
- Study in people2010Acceleration of Platelet Recovery Following Autologous Peripheral Blood Stem Cell Transplantation (TXA127)
This trial stopped before it finished and never published anything. It was a mid stage study of the peptide for speeding up platelet recovery after a stem cell transplant, run by Tarix Pharmaceuticals. 75 people had joined when it was halted. No results have been posted in the registry as of 11 September 2026. A trial that ends this way leaves nothing a reader can learn from.
Phase 2, sponsor Tarix Pharmaceuticals, 75 participants enrolled, status TERMINATED, no results posted as of 11 September 2026.
- Study in people2013Efficacy Study of TXA127 to Reduce Graft-vs-Host Disease in Subjects Undergoing Allogeneic Transplant
This trial was called off before a single person joined it. It was planned as a mid stage study of the peptide in people having a donor stem cell transplant, to see whether it reduced graft versus host disease. Two more transplant studies of the same peptide were also withdrawn with nobody enrolled. Nothing was learned, because nothing was done. The record sits here to show how much of this programme never happened.
Phase 2, sponsor Tarix Pharmaceuticals, status WITHDRAWN with zero participants enrolled. Two further TXA127 transplant trials, NCT01882374 and NCT01554254, are also listed WITHDRAWN with zero enrolment.
- Study in people2023TXA127 in Non-Ambulant Patients With Duchenne Muscular Dystrophy Cardiomyopathy
This study is on the books and nobody outside knows whether it is still running. It plans to give the peptide to 10 boys with Duchenne muscular dystrophy who can no longer walk and whose hearts are affected. The sponsor is Constant Therapeutics. On 11 September 2026 the registry listed its status as unknown, which means the sponsor has not confirmed it recently. There are no results to report.
Phase 2, sponsor Constant Therapeutics, 10 participants planned. Status was UNKNOWN on 11 September 2026, meaning the record has not been verified recently by the sponsor.
- Review of studies2016Therapeutic uses for Angiotensin-(1-7)
A review of the business and patent picture for the peptide and its lab-built cousins. It lays out the ACE2 and Mas receptor reasoning the drug program was built on.
Review of the therapeutic and patent landscape for the peptide and its analogues, describing the ACE2 and Mas receptor rationale that the clinical programme was built on.
Where to buy Angiotensin-(1-7)
No seller we track lists Angiotensin-(1-7) yet. We read sellers’ public product lists every week, and this section fills in as soon as one does. Every seller, graded
Common questions
Has Angiotensin-(1-7) been tested in people?
Yes. 76 people given it across 5 completed trials cited here, 1 of which found nothing. Angiotensin-(1-7) is the brake on the body's main blood pressure system.
What is the Angiotensin-(1-7) dosage?
No human dose established. Amounts that were given in studies sit in Human evidence on this page. None of them is a personal dose. 5 completed trials, 76 people given it
Is Angiotensin-(1-7) FDA-approved?
Not approved by the FDA for any use. It was tested in people under the name TXA127. No application to sell it has been approved, and no angiotensin-(1-7) product showed up when we checked the FDA drug database (Drugs@FDA) on 11 September 2026.
Has angiotensin-(1-7) been given to humans?
Yes. At least four published studies have given it to people. There was an early study in 18 adults with advanced cancer and a dose study around breast cancer chemo. There was a study in 20 people with sarcoma that had spread. And an intensive care study during COVID-19 signed up 107 people across its two stages.
Is it safe?
It has not been studied well enough to say. In the first cancer study, the top dose of 700 micrograms per kilogram caused a severe stroke in one person and nerve damage in the head in another, which healed. In the COVID-19 study, one person had a slow heartbeat that may have been caused by the drug and had to stop. Fewer than 200 people have ever been given it in published studies, all of them seriously ill.
Does it protect the heart or reverse fibrosis in people?
No published human study has tested that. The heart protection and anti-scarring evidence comes from rats and mice. The human studies are in cancer, transplants and COVID-19.
Is it approved anywhere?
No. It is still experimental. The company program, under the code TXA127, includes three studies cancelled with nobody signed up and three stopped early. None of the finished studies has posted results in the registry.